Alcidion Group (ALC) Stock Price, News & Analysis

Company Overview

Alcidion Group Limited, together with its subsidiaries, engages in the development and licensing of healthcare software products in Australia, New Zealand, and the United Kingdom. The company offers Miya Precision, a consolidated fast healthcare interoperability resource (FHIR) based platform to deliver smart healthcare; Smartpage, a smartphone and web-based system for hospital communication and task management to address the requirements of clinical and non-clinical users; Patientrack, a real-time patient monitoring and risk screening solution; Silverlink, a patient administration system; and ExtraMed, a clinical and patient flow management software. It also provides product implementation, product support and maintenance, systems integration, and data analysis services. The company was formerly known as Alcidion Corporation Pty Ltd and changed its name to Alcidion Group Limited in December 2015. Alcidion Group Limited was founded in 2000 and is headquartered in South Yarra, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 1.21 million shs
• Average Volume: N/A
• Market Capitalization: A$110.12 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ALC Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Alcidion Group own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Alcidion Group investors own include Revvity (PKI), Gray Media (GTN), (NESCQ) (NESCQ), Teradyne (TER), AbbVie (ABBV), Aphria (APHA) and AquaBounty Technologies (AQB).

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Health Information Services
• Sub-Industry: Medical Equipment
• Current Symbol: ASX:ALC
• CIK: N/A
• Web: www.alcidion.com
• Phone: 61 8 6489 1600
• Fax: N/A
• Employees: 25,200
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): A($0.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -A$8.42 million
• Net Margins: -22.71%
• Pretax Margin: N/A
• Return on Equity: -9.45%
• Return on Assets: -4.61%

Debt

• Debt-to-Equity Ratio: 1.95
• Current Ratio: 0.97
• Quick Ratio: 1.01

Sales & Book Value

• Annual Sales: A$37.06 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 9.41
• Book Value: A$0.06 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 1,340,000,000
• Free Float: N/A
• Market Cap: A$110.12 million
• Optionable: Not Optionable
• Beta: 1.47